Paul Reider - 13 Dec 2024 Form 4 Insider Report for Coherus BioSciences, Inc. (CHRS)

Role
Chief Commercial Officer
Signature
/s/ Bryan McMichael, as Attorney-in-Fact for Paul Reider
Issuer symbol
CHRS
Transactions as of
13 Dec 2024
Net transactions value
-$3,338
Form type
4
Filing time
17 Dec 2024, 16:44:12 UTC
Previous filing
24 Jul 2024
Next filing
07 Jan 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CHRS Common Stock Tax liability $3,338 -2,073 -2.3% $1.61 89,204 13 Dec 2024 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares automatically withheld by the Issuer to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. No shares were sold by the Reporting Person in connection with the foregoing transaction.
F2 Includes 5,000 shares acquired on November 15, 2024 and 5,000 shares acquired on May 15, 2024, each pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan.